MARKET

ASMB

ASMB

Assembly Bioscie
NASDAQ
15.51
+0.08
+0.52%
Closed 16:00 06/12 EDT
OPEN
15.85
PREV CLOSE
15.43
HIGH
16.27
LOW
14.90
VOLUME
21.64K
TURNOVER
0
52 WEEK HIGH
20.04
52 WEEK LOW
7.69
MARKET CAP
85.51M
P/E (TTM)
-1.3821
1D
5D
1M
3M
1Y
5Y
Assembly Biosciences Doses First Participant In Phase 1a/b Trial Of HSV Inhibitor ABI-5366
ABI-5366 is being developed for the treatment of recurrent genital herpes. The drug is in a Phase 1a study in healthy participants and a phase 1b study in people with recurrent herpes. ABI- 5366 is expected to be approved in 2024 for human testing.
Benzinga · 2d ago
ASSEMBLY BIOSCIENCES INC: INTERIM DATA FROM PHASE 1A STUDY EXPECTED IN Q3 2024
Reuters · 2d ago
ASSEMBLY BIOSCIENCES DOSES FIRST PARTICIPANT IN PHASE 1A/B CLINICAL TRIAL OF HERPES SIMPLEX VIRUS HELICASE-PRIMASE INHIBITOR CANDIDATE ABI-5366
Reuters · 2d ago
Weekly Report: what happened at ASMB last week (0603-0607)?
Weekly Report · 3d ago
Assembly Biosciences Enhances Stock Plans and Elects Board
TipRanks · 06/03 20:56
Weekly Report: what happened at ASMB last week (0527-0531)?
Weekly Report · 06/03 09:07
Assembly Bioscie: Statement of changes in beneficial ownership of securities
Press release · 05/30 22:11
Weekly Report: what happened at ASMB last week (0520-0524)?
Weekly Report · 05/27 09:07
More
About ASMB
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.

Webull offers Assembly Biosciences Inc stock information, including NASDAQ: ASMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASMB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ASMB stock methods without spending real money on the virtual paper trading platform.